IL1B and Cognitive impairment: Here, VX-765 reversed cognitive deficits without altering increased pro-inflammatory Iba1+-microglia, Il-1β, TNF-α, and GFAP+-astrocytes, thereby seemingly excluding inflammation as a driver of cognitive impairment.